Adherence to hydroxychloroquine in patients ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Adherence to hydroxychloroquine in patients with systemic lupus: contrasting results and weak correlation between assessment tools
Author(s) :
Hachulla, Eric [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Le Gouellec, Noémie [Auteur]
Centre hospitalier [Valenciennes, Nord]
Launay, David [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Balquet, Marie-Helene [Auteur]
GHT de l'Artois
Maillard, Hélène [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE (Ex-Liric)]
Azar, Raymond [Auteur]
Boldron, Amal [Auteur]
Bataille, Pierre [Auteur]
Centre Hospitalier Boulogne-sur-mer
Lambert, Marc [Auteur]
Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement (RID-AGE) - U1167
Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement (RID-AGE) - U1167
Buchdahl, Anne-Laure [Auteur]
Centre Hospitalier [Douai, Nord]
Allorge, Delphine [Auteur]
IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483
Hatron, Pierre-Yves [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE (Ex-Liric)]
Sobanski, Vincent [Auteur]
Lille Inflammation Research International Center (LIRIC) - U995
Hennart, Benjamin [Auteur]
IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483
Clerson, Pierre [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Morell-Dubois, Sandrine [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Le Gouellec, Noémie [Auteur]
Centre hospitalier [Valenciennes, Nord]
Launay, David [Auteur]

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Balquet, Marie-Helene [Auteur]
GHT de l'Artois
Maillard, Hélène [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE (Ex-Liric)]
Azar, Raymond [Auteur]
Boldron, Amal [Auteur]
Bataille, Pierre [Auteur]
Centre Hospitalier Boulogne-sur-mer
Lambert, Marc [Auteur]

Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement (RID-AGE) - U1167
Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement (RID-AGE) - U1167
Buchdahl, Anne-Laure [Auteur]
Centre Hospitalier [Douai, Nord]
Allorge, Delphine [Auteur]
IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483
Hatron, Pierre-Yves [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE (Ex-Liric)]
Sobanski, Vincent [Auteur]

Lille Inflammation Research International Center (LIRIC) - U995
Hennart, Benjamin [Auteur]

IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483
Clerson, Pierre [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Morell-Dubois, Sandrine [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Journal title :
Joint Bone Spine
Abbreviated title :
Joint Bone Spine
Volume number :
87
Pages :
603-610
Publication date :
2020-05-10
ISSN :
1778-7254
Keyword(s) :
Adherence
Systemic Lupus Hydroxychloroquine
Systemic Lupus Hydroxychloroquine
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
OBJECTIVE: Hydroxychloroquine (HCQ) is an anchor drug in the treatment of systemic lupus erythematosus (SLE). Adherence to HCQ is key for efficacy. Inaccurate evaluation of adherence could lead to non-justified switch to ...
Show more >OBJECTIVE: Hydroxychloroquine (HCQ) is an anchor drug in the treatment of systemic lupus erythematosus (SLE). Adherence to HCQ is key for efficacy. Inaccurate evaluation of adherence could lead to non-justified switch to more expensive or less tolerated drugs. METHODS: Severe non-adherence rate to HCQ was estimated in a sample of SLE patients during a routine visit using blood HCQ concentration<200μg/L. Adherence was assessesd by the Medication Adherence Self-Report Inventory (MASRI)<80/100, 8-item Morisky Medication Adherence Scale (MMAS-8) ≤6/8, Health Care Provider (HCP) visual analog scale (VAS)<80/100. Same procedures were to be repeated during a further routine visit 6 to 12 months later. We described agreement and correlations between tools and compared severely non-adherent patients and others on their characteristics. RESULTS: The study involved 158 patients (86.1% females) aged 42.2±12.6 years treated with HCQ for 9.6±6.9 years. Blood HCQ concentration (mean±standard deviation) was 1046±662μg/L at visit 1 and 855±577μg/L at visit 2. At visit 1, the non-adherence rate varied from 3.2% (blood HCQ level<200μg/L) to 7.7% (MASRI), 12.4% (HCP-VAS) or 32.5% (MMAS-8). 37.8% of patients met at least one of the definitions of non-adherence. Patients' characteristics including SLE activity, damage and quality of life were similar between severely non-adherent patients and others. Correlations between blood HCQ-concentration and self-questionnaires were weak (r<0.25) and agreement between methods was poor. CONCLUSIONS: Blood HCQ concentration<200μg/L reveals severe non-adherence. Combining blood HCQ concentration with MASRI and MMAS-8 may help to better identify non-adherence in SLE. Agreement between methods was poor and correlations with HCQ level and SLE activity were weak.Show less >
Show more >OBJECTIVE: Hydroxychloroquine (HCQ) is an anchor drug in the treatment of systemic lupus erythematosus (SLE). Adherence to HCQ is key for efficacy. Inaccurate evaluation of adherence could lead to non-justified switch to more expensive or less tolerated drugs. METHODS: Severe non-adherence rate to HCQ was estimated in a sample of SLE patients during a routine visit using blood HCQ concentration<200μg/L. Adherence was assessesd by the Medication Adherence Self-Report Inventory (MASRI)<80/100, 8-item Morisky Medication Adherence Scale (MMAS-8) ≤6/8, Health Care Provider (HCP) visual analog scale (VAS)<80/100. Same procedures were to be repeated during a further routine visit 6 to 12 months later. We described agreement and correlations between tools and compared severely non-adherent patients and others on their characteristics. RESULTS: The study involved 158 patients (86.1% females) aged 42.2±12.6 years treated with HCQ for 9.6±6.9 years. Blood HCQ concentration (mean±standard deviation) was 1046±662μg/L at visit 1 and 855±577μg/L at visit 2. At visit 1, the non-adherence rate varied from 3.2% (blood HCQ level<200μg/L) to 7.7% (MASRI), 12.4% (HCP-VAS) or 32.5% (MMAS-8). 37.8% of patients met at least one of the definitions of non-adherence. Patients' characteristics including SLE activity, damage and quality of life were similar between severely non-adherent patients and others. Correlations between blood HCQ-concentration and self-questionnaires were weak (r<0.25) and agreement between methods was poor. CONCLUSIONS: Blood HCQ concentration<200μg/L reveals severe non-adherence. Combining blood HCQ concentration with MASRI and MMAS-8 may help to better identify non-adherence in SLE. Agreement between methods was poor and correlations with HCQ level and SLE activity were weak.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Inserm
Institut Pasteur de Lille
Université de Lille
Inserm
Institut Pasteur de Lille
Université de Lille
Collections :
Submission date :
2021-07-06T12:48:36Z
2022-11-30T09:36:12Z
2022-11-30T09:36:12Z
Files
- Hachulla et al.pdf
- Version finale acceptée pour publication (postprint)
- Open access
- Access the document